Dashboard
Manage Tickers

CMPS COMPASS Pathways plc

Nasdaq compasspathways.com


$ 6.43 $ 0.00 (0 %)    

Wednesday, 05-Nov-2025 05:55:37 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 615.70 $ 0.00 (0 %)
DIA $ 470.37 $ 0.00 (0 %)
SPY $ 672.90 $ 0.00 (0 %)
TLT $ 89.94 $ 0.00 (0 %)
GLD $ 364.77 $ 0.00 (0 %)
$ 6.63
$ 6.52
$ 6.41 x 200
$ 6.56 x 1
-- - --
$ 2.25 - $ 7.09
12,414,513
na
636.59M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

correction-compass-pathways-q3-adj-eps-038-beats-039-estimate
CORRECTION: Compass Pathways Q3 Adj. EPS $...
11/04/2025 14:38:49

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0....

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 12:05:48

compass-pathways-said-its-accelerating-commercialization-readiness-plans-by-9-12-months-it-has-completed-comp006-trial-enrollment-and-meeting-with-fda-on-marketing-application-submission-strategies-for-comp360-in-treatment-resistant-depression-including-potential-rolling-submission
Compass Pathways Said Its Accelerating Com...
11/04/2025 11:38:28

COMP360 psilocybin treatment in TRD (Treatment Resistant Depression)Second Phase 3 trial, COMP006, has completed enrollment (n=...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

neurokaire-enters-rd-collaboration-with-compass-pathways-to-advance-precision-psychiatry-and-neurology
NeuroKaire Enters R&D Collaboration With C...
10/30/2025 12:38:56

Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance ne...

Core News & Articles
'Psychedelics Show Promise As An 'Entirely...
10/13/2025 17:28:47

https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-sugge...

btig-maintains-buy-on-compass-pathways-raises-price-target-to-14
BTIG Maintains Buy on Compass Pathways, Ra...
10/13/2025 17:17:42

BTIG analyst Thomas Shrader maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $7 to $14.

Core News & Articles
'New York Lawmakers Hold Hearing Psilocybi...
10/02/2025 15:03:14

https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedel...

Core News & Articles
'Massachusetts Lawmakers Approve Bill To C...
09/12/2025 16:30:15

https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/

compass-pathways-says-open-label-phase-2-study-shows-single-25-mg-comp360-psilocybin-dose-was-well-tolerated-with-no-serious-adverse-events-observed-and-indicated-both-rapid-and-durable-improvement-in-symptoms-from-baseline-observed-out-to-12-weeks-following-single-administration
Compass Pathways Says Open-Label Phase 2 S...
09/02/2025 10:35:08

Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovati...

compass-pathways-publishes-results-from-open-label-phase-2-study-evaluating-safety-and-tolerability-of-single-dose-of-25-mg-of-investigational-comp360-synthetic-psilocybin-treatment-in-22-patients-with-post-traumatic-stress-disorder
Compass Pathways Publishes Results From Op...
09/02/2025 10:33:03

Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observ...

Core News & Articles
'Military To Start Testing Service Members...
08/28/2025 18:16:26

https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/

Core News & Articles
'GOP Senator Is 'Confident' Psychedelics A...
08/22/2025 19:53:09

https://www.marijuanamoment.net/gop-senator-is-confident-psychedelics-access-will-expand-under-trump-saying-many-veterans-speak...

Core News & Articles
'U.S. Senate Committee To Hold Hearing On ...
08/21/2025 18:35:07

https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/

hc-wainwright--co-maintains-buy-on-compass-pathways-lowers-price-target-to-40
HC Wainwright & Co. Maintains Buy on Compa...
08/04/2025 16:30:31

HC Wainwright & Co. analyst Patrick Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price ta...

canaccord-genuity-maintains-buy-on-compass-pathways-maintains-15-price-target
Canaccord Genuity Maintains Buy on Compass...
08/01/2025 15:08:06

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $15 price target.

compass-pathways-q2-eps-041-beats-044-estimate
Compass Pathways Q2 EPS $(0.41) Beats $(0....
07/31/2025 10:30:25

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0....

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

Core News & Articles
'Massachusetts Psychiatric Society Endorse...
07/29/2025 16:06:29

https://www.marijuanamoment.net/massachusetts-psychiatric-society-endorses-bill-to-decriminalize-psilocybin-possession/

Core News & Articles
'California Governor He's 'All In' On Psyc...
07/21/2025 14:21:31

https://www.marijuanamoment.net/california-governor-hes-all-in-on-psychedelic-therapy-access-but-worries-about-capitalists-comm...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION